Related Clinical Trials

ARTESIA found apixaban reduced stroke or systemic embolism versus aspirin in patients with subclinical AF and CHA2DS2-VASc of at least 3, while increasing major bleeding risk. CRYSTAL AF previously found ICM to be 8.8 times more effective than standard of care for detecting atrial fibrillation in cryptogenic stroke patients. STROKE AF enrolled 492 patients with stroke attributed to LAD or SVD. ATTICUS found no significant difference in new ischemic lesions between empirical DOAC therapy and ICM-monitored aspirin therapy switching to DOAC after AF detection, but was underpowered for recurrent stroke differences. PER DIEM found numerically fewer recurrent strokes with ICM monitoring than with external loop recorder monitoring, but was underpowered and did not establish a significant benefit.